Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia-Reference-Cited by-同舟云学术

Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia

Published:2017-07-11 Issue:5 Volume:142 Page:756-766
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:J. Neurochem.

Author:

Havelund Jesper F.¹²,Andersen Andreas D.³⁴⁵⁶^ORCID,Binzer Michael³⁴,Blaabjerg Morten⁷⁸,Heegaard Niels H.H.⁸⁹¹⁰,Stenager Egon³⁴,Faergeman Nils J.²,Gramsbergen Jan Bert¹^ORCID

Affiliation:

1. Neurobiology Research; Institute of Molecular Medicine; University of Southern Denmark; Odense Denmark

2. Department of Biochemistry and Molecular Biology; VILLUM Center for Bioanalytical Sciences; University of Southern Denmark; Odense Denmark

3. Institute of Regional Health Research; University of Southern Denmark; Odense Denmark

4. Focused Research Unit in Neurology; Hospital of Southern Jutland; Aabenraa Denmark

5. Department of Neurology; Hospital of Southern Jutland; Sønderborg Denmark

6. Odense Patient data Exploratory Network (OPEN); Odense University Hospital; Odense Denmark

7. Department of Neurology; Odense University Hospital; Odense Denmark

8. Institute of Clinical Research; University of Southern Denmark; Odense Denmark

9. Department of Clinical Biochemistry and Pharmacology; Odense University Hospital; Odense Denmark

10. Department of Autoimmunology & Biomarkers; Statens Serum Institut; Copenhagen Denmark

Funder

Michael J. Fox Foundation for Parkinson's Research

Danish Parkinson Society

Villum Fonden

Region of Southern Denmark

SDU Health Sciences Faculty and Hospital Southern Jutland

Fonden til Laegevidenskabens Fremme

Danske Bank's Foundation

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jnc.14104/fullpdf

Reference49 articles.

1. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum;Amori;Neuroscience,2009

2. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia;Andersen;J. Neurochem.,2017

3. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA;Asanuma;BMC Neurosci.,2016

4. Urate as a predictor of the rate of clinical decline in Parkinson disease;Ascherio;Arch. Neurol.,2009

5. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease;Bastide;Prog. Neurobiol.,2015

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid;ACS Chemical Neuroscience;2024-01-09

2. Metabolomics in neurodegenerative disorders—Parkinson’s disease;Comprehensive Analytical Chemistry;2024

3. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease;Molecular Neurodegeneration;2023-12-19

4. Exploring the interplay between metabolomics and genetics in Parkinson's disease: Insights from ongoing research and future avenues;Mechanisms of Ageing and Development;2023-12

5. Kynurenine pathway and its role in neurologic, psychiatric, and inflammatory bowel diseases;Molecular Biology Reports;2023-10-18